Tajuana Bradley has served on speakers bureaus for ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Coherus, G1 Therapeutics, Puma Biotechnology, and Seagen.
Evaluate pivotal clinical trials leading to recent FDA approvals of new molecular targeted treatment options for patients with metastatic non-small cell lung cancer (NSCLC), and related updates to clinical practice guidelines.
Differentiate recently validated predictive and prognostic biomarkers and their clinical relevance for treating patients with mNSCLC.
Integrate evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with mNSCLC.
these are already done
Georgia Cancer Specialists, Gwinnett and Cumming Office. Affiliated with Northside Hospital Cancer Institute
Nurse Practitioner Thoracic Oncology,
Abramson Cancer Center, Hospital of the University of Pennsylvania
You must be logged in and own this session in order to